

LEGISLATIVE FISCAL OFFICE
Fiscal Note



Fiscal Note On: **SB 236** SLS 26RS 499

Bill Text Version: **ENGROSSED**

Opp. Chamb. Action:

Proposed Amd.:

Sub. Bill For.:

Date: March 24, 2026 8:24 AM	Author: OWEN, ROBERT
Dept./Agy.: Louisiana Department of Health	Analyst: Anthony Shamis
Subject: Provides relative to kidney disease	

HEALTH CARE

EG NO IMPACT See Note

Page 1 of 1

Provides relative to kidney disease. (8/1/26)

Proposed law requires the Louisiana Department of Health (LDH) to conduct an annual review of all medications and forms of treatment for chronic and rare kidney disease that are eligible for coverage under Medicaid. The annual review will determine if the available covered medications, treatments, and services are adequate to meet the needs of enrollees with a diagnosis of chronic or rare kidney disease, and whether the department should seek to add additional medications, treatments, or services. Proposed law requires LDH to solicit and consider public input as part of the review process, with specific emphasis on individuals or organizations with knowledge or expertise in the area of chronic and rare kidney diseases. Proposed law requires LDH to examine and pursue strategic partnerships with state-based entities that represent or provide services to individuals living with chronic and rare kidney diseases in order to increase awareness and screening through new or existing initiatives, such as Well-Ahead Louisiana. Proposed law requires LDH to submit a report detailing the findings of the annual review and any recommendations to the legislature on or before July 1, 2027, and annually thereafter. The report shall be submitted to the president of the Senate, the speaker of the House of Representatives, the Senate and House Health and Welfare Committees, and the David R. Poynter Legislative Research Library. LDH is required to publish the annual report on its website.

EXPENDITURES	2026-27	2027-28	2028-29	2029-30	2030-31	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

REVENUES	2026-27	2027-28	2028-29	2029-30	2030-31	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

EXPENDITURE EXPLANATION

There is no anticipated direct material effect on governmental expenditures as a result of this measure. LDH indicates that administrative activities associated with implementation, including conducting the required annual review, soliciting and considering public input, evaluating strategic partnerships, and preparing the required report, can be absorbed within existing staff and resources. Any costs associated with the required annual review will be funded through LDH's existing External Quality Review Organization (EQRO) contract. Accordingly, no additional state expenditures are anticipated.

Proposed law requires LDH to conduct an annual review of all medications and forms of treatment for chronic and rare kidney disease that are eligible for coverage under Medicaid. Proposed law further requires LDH to consider public input, examine and pursue strategic partnerships with state-based entities, submit an annual report to the legislature, and publish the report on its website.

REVENUE EXPLANATION

There is no anticipated direct material effect on governmental revenues as a result of this measure.

Senate

Dual Referral Rules

House

13.5.1 >= \$100,000 Annual Fiscal Cost {S & H}

6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}

13.5.2 >= \$500,000 Annual Tax or Fee Change {S & H}

6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

Alan M. Boxberger

Alan M. Boxberger
Legislative Fiscal Officer